Lumbar Spinal Fibrosis and TNF Alpha Inhibition

Lumbar Spinal Fibrosis and TNF Alpha Inhibition

This study is currently recruiting patients.
Verified by Assistance Publique - Hôpitaux de Paris April 2007

Sponsored by: Assistance Publique - Hôpitaux de Paris
Information provided by: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT00385086

clinical trials Purpose

TNF-alpha is the main cytokine implicated in the formation of lumbar spinal fibrosis. Inhibiting TNF-alpha could significantly decrease spinal fibrosis after lumbar discectomy.
Condition Intervention Phase
Post Operative Sciatica by Lumbar Spinal Fibrosis
 Drug: TNF blocker
Phase III

MedlinePlus consumer health information 

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study

Official Title: Efficacy of TNF-Alpha Inhibition in Sciatica With Post-Operative Lumbar Spinal Fibrosis

Further study details as provided by Assistance Publique - Hôpitaux de Paris:
Primary Outcome Measures: 
  • Sciatica pain

Secondary Outcome Measures: 
  • Functional assessments

Total Enrollment:  40

Study start: February 2007;  Expected completion: November 2008

OBJECT:

Failed back surgery syndrome is still a challenging therapeutic problem. Clinical studies have demonstrated a significant association between lumbar spinal fibrosis after lumbar discectomy and the recurrence of radicular pain in 25% of cases. Forceful epidural infiltrations, radiotherapy, therapy with D-penicillamine or surgical procedures have had unfavourable results in terms of pain and cost. Magnetic resonance imaging reveals lumbar spinal fibrosis by a hyposignal in the T1 sequence and a hypersignal in T2 sequence around the spinal tissue. Tumor necrosis factor a (TNF-a) is the main cytokine implicated in the formation of tissue fibrosis. In animal models of fibrosis, TNF-a inhibition has been shown to prevent and treat tissue fibrosis.

HYPOTHESIS:

Inhibiting TNF-a could significantly decrease sciatica pain because of lumbar spinal fibrosis after lumbar discectomy by decreasing spinal fibrosis.

METHODS:

We propose a 2-year pilot prospective, randomized, double-blind, controlled study of TNF-a inhibitor (infliximab) in patients with sciatica as a result of postoperative lumbar spinal fibrosis. The infliximab group will receive one intravenous injection of 3 mg/kg infliximab. The control group will receive one physiological serum injection. Patients will be evaluated at day 0, 10, 30, 90, and 180. The main evaluation criterion will be sciatica pain as measured on a visual analog scale, with the objective of a 50% decrease in pain at day 10. This objective leads to a size of 20 patients per group. The other evaluation criteria will be clinical, functional, social, and professional. Patients will be recruited from the rehabilitation unit at Cochin teaching hospital.

clinical trials Eligibility

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both
Criteria

Inclusion Criteria:

  • age over 18 years old
  • sciatica post discectomy
  • Pain with VAS > 40 mm and impossibility to have his usual activity
  • Surgical discectomy (less than 2 years and more than 6 months)
  • Painless of more than one month and less than one year after the discectomy
  • MRI with gadolinium injection of less than 6 months and done more than 6 months after the discectomy
  • Presence of spinal fibrosis on MRI (hyposignal in T1 enhanced by gadolinium and hypersignal in T2)
  • failure of epidural injection treatment
  • absence of tuberculosis
  • contraception for woman
  • informed consent

Exclusion Criteria:

  • Chronic psychiatric pathologies not treated
  • Presence of conflict between nerve root and herniated disc or disc fragments or spinal stenosis
  • severe cognitives troubles
  • severe cardiac failure (class III or IV)
  • Tuberculosis (active or latent), severe infections
  • Cancers
  • Allergy reactions to the drug studied
  • Difficulties to understand french
  • Patients enrolled in another clinical trial in the past three months
  • pregnancy, breastfeeding or no contraception

clinical trials Location and Contact Information

Please refer to this study by ClinicalTrials.gov identifier  NCT00385086

Francois Rannou, MD, PhD      +33158412535    francois.rannou@cch.aphp.fr
Raphael Serreau, MD      +33158411180    raphael.serreau@cch.aphp.fr

France
      Hopital Cochin, Paris,  75014,  France; Recruiting
Serge Poiraudeau, MD, PhD,  Sub-Investigator
Michel Revel, MD,  Sub-Investigator

Study chairs or principal investigators

Francois Rannou, MD, PhD,  Principal Investigator,  AP-HP   

clinical trials More Information

Study ID Numbers:  P050312
Last Updated:  April 30, 2007
Record first received:  October 4, 2006
ClinicalTrials.gov Identifier:  NCT00385086
Health Authority: France: Afssaps - French Health Products Safety Agency
ClinicalTrials.gov processed this record on June 12, 2007
Last Updated: 06/19/2007
What is This?

Related Articles on this Topic